# Palvella Therapeutics, Inc.: financial statements, quarterly

PVLA · Nasdaq · CIK 1583648 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pvla.md) · [Financials](/companies/pvla/financials.md) · [Filings](/companies/pvla/filings.md) · [Insiders](/companies/pvla/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pvla/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [19.5](/filings/0001437749-24-034891.md) | [1.3 d](/filings/0001437749-24-010123.md) | [0.1](/filings/0001437749-24-017037.md) | [0.0](/filings/0001437749-24-026778.md) | [0.0](/filings/0001437749-24-034891.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [9.6](/filings/0001437749-23-031957.md) | [(28.6) d](/filings/0000950170-25-047212.md) | [1.0](/filings/0000950170-25-071998.md) | [1.4](/filings/0000950170-25-108438.md) | [3.2](/filings/0001193125-25-276119.md) | [2.5 d](/filings/0001193125-26-133372.md) | [4.1](/filings/0001193125-26-210463.md) | [5.1](/filings/0001193125-26-331574.md) | [6.5](/filings/0001193125-25-276119.md) | [7.1 d](/filings/0001193125-26-133372.md) | [9.3](/filings/0001193125-26-210463.md) | [12.5](/filings/0001193125-26-331574.md) |
| Operating income | $m | [(11.8)](/filings/0001437749-24-034891.md) | [13.4 d](/filings/0000950170-25-047212.md) | [(1.8)](/filings/0000950170-25-071998.md) | [(2.9)](/filings/0000950170-25-108438.md) | [(5.1)](/filings/0001193125-25-276119.md) | [(4.4) d](/filings/0001193125-26-133372.md) | [(7.9)](/filings/0001193125-26-210463.md) | [(9.3)](/filings/0001193125-26-331574.md) | [(10.2)](/filings/0001193125-25-276119.md) | [(11.3) d](/filings/0001193125-26-133372.md) | [(14.9)](/filings/0001193125-26-210463.md) | [(21.4)](/filings/0001193125-26-331574.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | [0.0](/filings/0000950170-25-071998.md) | [0.0](/filings/0000950170-25-108438.md) | [0.0](/filings/0001193125-25-276119.md) | [0.0 d](/filings/0001193125-26-133372.md) | [0.0](/filings/0001193125-26-210463.md) | [0.0](/filings/0001193125-26-331574.md) | [0.0](/filings/0001193125-25-276119.md) | [0.0 d](/filings/0001193125-26-133372.md) | [0.0](/filings/0001193125-26-210463.md) | [0.0](/filings/0001193125-26-331574.md) |
| Net income | $m | [(10.8)](/filings/0001437749-24-034891.md) | [38.7 d](/filings/0000950170-25-047212.md) | [(2.5)](/filings/0001193125-25-276119.md) | [(4.2)](/filings/0001193125-25-276119.md) | [(6.8)](/filings/0001193125-25-276119.md) | [(4.0) d](/filings/0001193125-26-133372.md) | [(8.2)](/filings/0001193125-26-331574.md) | [(9.5)](/filings/0001193125-26-331574.md) | [(11.3)](/filings/0001193125-25-276119.md) | [(12.7) d](/filings/0001193125-26-133372.md) | [(15.8)](/filings/0001193125-26-331574.md) | [(21.9)](/filings/0001193125-26-331574.md) |
| Diluted EPS | $ per share | [(8.70)](/filings/0001437749-24-034891.md) | not reported | [(1.54)](/filings/0000950170-25-071998.md) | [(2.47)](/filings/0000950170-25-108438.md) | [(3.94)](/filings/0001193125-25-276119.md) | not reported | [(0.74)](/filings/0001193125-26-210463.md) | [(0.86)](/filings/0001193125-26-331574.md) | [(1.03)](/filings/0001193125-25-276119.md) | not reported | [(1.20)](/filings/0001193125-26-210463.md) | [(1.52)](/filings/0001193125-26-331574.md) |
| Basic EPS | $ per share | [(8.70)](/filings/0001437749-24-034891.md) | not reported | [(1.54)](/filings/0000950170-25-071998.md) | [(2.47)](/filings/0000950170-25-108438.md) | [(3.94)](/filings/0001193125-25-276119.md) | not reported | [(0.74)](/filings/0001193125-26-210463.md) | [(0.86)](/filings/0001193125-26-331574.md) | [(1.03)](/filings/0001193125-25-276119.md) | not reported | [(1.20)](/filings/0001193125-26-210463.md) | [(1.52)](/filings/0001193125-26-331574.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [32.9](/filings/0001437749-23-031957.md) | [7.4](/filings/0000950170-25-047212.md) | [19.1](/filings/0001437749-24-017037.md) | [19.7](/filings/0001437749-24-026778.md) | [19.4](/filings/0001437749-24-034891.md) | [83.6](/filings/0001193125-26-133372.md) | [75.6](/filings/0000950170-25-071998.md) | [70.4](/filings/0000950170-25-108438.md) | [63.6](/filings/0001193125-25-276119.md) | [58.0](/filings/0001193125-26-331574.md) | [206](/filings/0001193125-26-210463.md) | [188](/filings/0001193125-26-331574.md) |
| Current assets | $m | [59.1](/filings/0001437749-23-031957.md) | [7.5](/filings/0000950170-25-047212.md) | not reported | not reported | not reported | [88.2](/filings/0001193125-26-133372.md) | [79.4](/filings/0000950170-25-071998.md) | [73.7](/filings/0000950170-25-108438.md) | [66.9](/filings/0001193125-25-276119.md) | [59.0](/filings/0001193125-26-331574.md) | [263](/filings/0001193125-26-210463.md) | [253](/filings/0001193125-26-331574.md) |
| Total assets | $m | [59.4](/filings/0001437749-23-031957.md) | [7.5](/filings/0000950170-25-047212.md) | [29.5](/filings/0001437749-24-017037.md) | [25.1](/filings/0001437749-24-026778.md) | [20.5](/filings/0001437749-24-034891.md) | [88.2](/filings/0001193125-26-133372.md) | [79.4](/filings/0000950170-25-071998.md) | [73.7](/filings/0000950170-25-108438.md) | [66.9](/filings/0001193125-25-276119.md) | [59.6](/filings/0001193125-26-331574.md) | [264](/filings/0001193125-26-210463.md) | [254](/filings/0001193125-26-331574.md) |
| Current liabilities | $m | [28.9](/filings/0001437749-23-031957.md) | [2.4](/filings/0000950170-25-047212.md) | [7.5](/filings/0001437749-24-017037.md) | [6.3](/filings/0001437749-24-026778.md) | [4.3](/filings/0001437749-24-034891.md) | [12.0](/filings/0001193125-26-133372.md) | [9.0](/filings/0000950170-25-071998.md) | [9.6](/filings/0000950170-25-108438.md) | [10.3](/filings/0001193125-25-276119.md) | [11.3](/filings/0001193125-26-331574.md) | [9.1](/filings/0001193125-26-210463.md) | [11.9](/filings/0001193125-26-331574.md) |
| Total liabilities | $m | [28.9](/filings/0001437749-23-031957.md) | [11.4](/filings/0000950170-25-047212.md) | not reported | not reported | not reported | [25.6](/filings/0001193125-26-133372.md) | [23.9](/filings/0000950170-25-071998.md) | [26.0](/filings/0000950170-25-108438.md) | [28.3](/filings/0001193125-25-276119.md) | [31.6](/filings/0001193125-26-331574.md) | [31.4](/filings/0001193125-26-210463.md) | [36.6](/filings/0001193125-26-331574.md) |
| Shareholders' equity | $m | [30.5](/filings/0001437749-24-034891.md) | [(74.5)](/filings/0001193125-26-133372.md) | [(76.9)](/filings/0001193125-25-276119.md) | [(80.8)](/filings/0001193125-25-276119.md) | [(87.4)](/filings/0001193125-25-276119.md) | [62.6](/filings/0001193125-26-331574.md) | [55.6](/filings/0001193125-26-331574.md) | [47.8](/filings/0001193125-26-331574.md) | [38.7](/filings/0001193125-25-276119.md) | [28.0](/filings/0001193125-26-331574.md) | [232](/filings/0001193125-26-331574.md) | [217](/filings/0001193125-26-331574.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.7) d](/filings/0001437749-24-034891.md) | [20.4 d](/filings/0000950170-25-047212.md) | [(1.1)](/filings/0000950170-25-071998.md) | [(1.6) d](/filings/0000950170-25-108438.md) | [(2.7) d](/filings/0001193125-25-276119.md) | [(5.4) d](/filings/0001193125-26-133372.md) | [(6.8)](/filings/0001193125-26-210463.md) | [(5.4) d](/filings/0001193125-26-331574.md) | [(7.9) d](/filings/0001193125-25-276119.md) | [(4.9) d](/filings/0001193125-26-133372.md) | [(10.9)](/filings/0001193125-26-210463.md) | [(12.8) d](/filings/0001193125-26-331574.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001437749-24-034891.md) | [(0.0) d](/filings/0001437749-24-010123.md) | [0.0](/filings/0001437749-24-017037.md) | [0.0 d](/filings/0001437749-24-026778.md) | [0.0 d](/filings/0001437749-24-034891.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [73.7](/filings/0001583648-22-000025.md) | [74.1](/filings/0001437749-23-023085.md) | [1.1](/filings/0001437749-24-026778.md) | [1.2](/filings/0001437749-24-034891.md) | [1.8](/filings/0000950170-25-071998.md) | [1.8](/filings/0000950170-25-108438.md) | [1.8](/filings/0001193125-25-276119.md) | [11.0](/filings/0001193125-26-210463.md) | [11.1](/filings/0001193125-26-331574.md) | [11.1](/filings/0001193125-25-276119.md) | [13.1](/filings/0001193125-26-210463.md) | [14.4](/filings/0001193125-26-331574.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 14,408,407 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-331574.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.